PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
A randomized, double-blind, placebo controlled, two period crossover study to investigate the pharmacokinetics, tolerability and cognitive effects of 8 days dosing of CNV1014802 in healthy young versus elderly male and female subjects. Treatment periods will be separated by 13 days. The primary outcome measures are pharmacokinetics (PK) and tolerability.
Epistemonikos ID: cf2cf7f8c2d9648c252aa35502bdee8a4800cb70
First added on: May 12, 2024